抗结核药物性肝损伤易感基因研究进展

Research progress on susceptibility genes of anti-tuberculous drug-induced liver injury

结核病化疗疗程长,常用的抗结核治疗的一线药品(如异烟肼和利福平)均具有潜在的肝毒性,易引发抗结核药物性肝损伤(anti-tuberculosis drug-induced liver injury,ATLI),从而导致治疗效果低下和用药无效,继而诱发耐药结核病,增加治疗的困难及患者的负担。ATLI具有明显的个体差异性,而这种差异性很大程度上是由基因所引起的。但是国内尚没有对ATLI易感基因研究进展的相关综述,笔者通过对国内外ATLI易感基因的相关研究进展进行综述,为临床治疗及预防提供参考。

The course of tuberculosis chemotherapy is a long,and the first-line anti tuberculosis drugs commonly used(such as isoniazid and rifampicin)are potentially hepatotoxic and easily cause anti-tuberculosis druginduced liver injury(ATLI),which leads to low treatment efficacy and ineffective drug use,and then induces drugresistant tuberculosis,increasing the difficulty of treatment and the burden of patients.ATLI has obviously individual difference,which is mainly caused by genes.However,there is no relevant review on the progress of ATLI susceptibility genes research in China,the authors provide a reference for clinical treatment and prevention by reviewing the relevant research progress of ATLI susceptibility genes at home and abroad.